



Press Release

## ABIVAX Upcoming Events

### *2017 Financial Results to be announced on March 16, 2018*

**PARIS, Mar. 12, 2018, 8:30 pm. CET** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.

- March 12-14, 2018: BIO-Europe Spring in Amsterdam  
*Prof. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105*
- March 16, 2018: Full Year 2017 Financial Results
- March 19-20, 2018: BIO Asia International Conference in Tokyo
- April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco

#### About ABIVAX ([www.abivax.com/en](http://www.abivax.com/en))

**ABIVAX** is mobilizing the body's natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX\_

#### Contacts:

**ABIVAX**  
**Finance**  
Didier Blondel  
[didier.blondel@abivax.com](mailto:didier.blondel@abivax.com)  
+33 1 53 83 08 41


**Press Relations France**  
**ALIZE RP**  
Caroline Carmagnol/Aurore Gangloff  
[abivax@alizerp.com](mailto:abivax@alizerp.com)  
+33 6 64 18 99 59

**Investors Relations**  
**LifeSci Advisors**  
Chris Maggos  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254

**Press Relations US**  
**LifeSci Public Relations**

Matt Middleman, M.D.  
[matt@lifescipublicrelations.com](mailto:matt@lifescipublicrelations.com)

+1 646 627 8384



**Investors and Press Relations Germany**  
**MC Services AG**

Anne Hennecke  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

+49 211 529 252 22

**ABIVAX**